Zoetis (ZTS) Could Be 15% Undervalued Following Its 2026 Earnings Outlook Cut

Board appointment and earnings reset put Zoetis in focus

Zoetis (ZTS) is back on investor radars after management cut its 2026 earnings outlook due to softer demand in the U.S. companion animal business, a shift that sparked a sharp share price reaction.

Recent trading tells a mixed story. The 7 day share price return of 6.11% and 30 day gain of 11.18% hint at a short term rebound; however, the year to date share price decline of 36.96% and 1 year total shareholder return fall of 43.84% show momentum has been fading for a while, even as Zoetis affirms its dividend and refreshes its board.

Scan other animal health and defensively positioned healthcare stocks that are reacting to similar demand resets with our curated 32 resilient stocks with low risk scores for additional context around Zoetis.

For Zoetis, the question now is blunt. Is the recent rebound just sentiment snapping back after a harsh reset, or a clearer read on what this business is actually worth?

Most Popular Narrative: 14.6% Undervalued

On Simply Wall St, the leading narrative on Zoetis pegs fair value at $92.92 per share, which sits well above the last close at $79.38 and frames the recent reset as a potential mispricing rather than a permanent impairment.

On one hand it’s not a business that’s going to grow much; on the other hand, it’s also not likely to collapse catastrophically. Double-edged sword.

See why 29 investors see Zoetis as 15% undervalued.

Result: Fair Value of $92.92 (UNDERVALUED)

Still, two pressure points sit in the background for Zoetis. Debt funded buybacks and the 11% U.S. pet segment revenue decline could both challenge that undervalued storyline.

Find out about the key risks to this Zoetis narrative.

Next Steps

Mixed sentiment around Zoetis is clear, so move quickly to test the numbers, weigh the trade offs, and see the 4 key rewards and 1 important warning sign

Looking for more investment ideas beyond Zoetis?

Do not stop at Zoetis. Use this reset as a prompt to refresh your watchlist and line up the next set of opportunities before others move first.

• Target steady compounding by scanning quality companies trading below their estimated worth through the 33 high quality undervalued stocks.
• Stack potential income streams by reviewing a curated set of high yield payers in the 8 dividend fortresses.
• Guard against nasty surprises by focusing on financially robust businesses via the list of solid balance sheet and fundamentals (25 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com